Indraprastha Medical Corporation Intrinsic Value
INDRAMEDCO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹238.80 | ₹191.04 - ₹286.56 | -39.1% | EPS: ₹19.90, Sector P/E: 12x |
| Book Value Method | asset | ₹78.44 | ₹70.60 - ₹86.28 | -80.0% | Book Value/Share: ₹64.89, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹128.61 | ₹115.75 - ₹141.47 | -67.2% | Revenue/Share: ₹160.76, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹193.04 | ₹173.74 - ₹212.34 | -50.8% | EBITDA: ₹296.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹231.80 | ₹185.44 - ₹278.16 | -40.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹318.40 | ₹286.56 - ₹350.24 | -18.8% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹169.95 | ₹152.95 - ₹186.94 | -56.7% | Revenue Growth: 13.5%, Adj P/E: 8.5x |
| ROE Based Valuation | profitability | ₹318.26 | ₹286.43 - ₹350.09 | -18.9% | ROE: 30.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹129.78 | ₹116.80 - ₹142.76 | -66.9% | EPS: ₹19.90, BVPS: ₹64.89 |
Want to compare with current market value? Check INDRAMEDCO share price latest .
Valuation Comparison Chart
INDRAMEDCO Intrinsic Value Analysis
What is the intrinsic value of INDRAMEDCO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Indraprastha Medical Corporation (INDRAMEDCO) is ₹193.04 (median value). With the current market price of ₹392.20, this represents a -50.8% variance from our estimated fair value.
The valuation range spans from ₹78.44 to ₹318.40, indicating ₹78.44 - ₹318.40.
Is INDRAMEDCO undervalued or overvalued?
Based on our multi-method analysis, Indraprastha Medical Corporation (INDRAMEDCO) appears to be trading above calculated value by approximately 50.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 30.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.74x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Indraprastha Medical Corporation
Additional stock information and data for INDRAMEDCO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹157 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹200 Cr | ₹121 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹145 Cr | ₹91 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹94 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹27 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |